IR-Med Names New CEO and Closes $3 Million Private Placement

IR-Med Inc. appointed David W. G. Stewart chief executive officer, effective June 3 2026, the company disclosed in an 8-K filed with the SEC the same day.

The filing reports entry into a material definitive securities purchase agreement dated June 2 2026 with several institutional and accredited investors. Under the agreement IR-Med sold unregistered shares of common stock and warrants in a private placement that raised $3 million in gross proceeds.

Item 3.02 of the filing confirms the securities were issued in reliance on exemptions from registration under Section 4(a)(2) and Regulation D.

Operationally the company transitions from its prior chief executive to Stewart, whose prior role is not detailed in the filing. The board simultaneously elected Stewart to the board of directors. No reason for the leadership change is cited. The private placement closes the previously announced financing and supplies working capital the company will use for product development and general corporate purposes.

The new shares and warrant shares remain unregistered. IR-Med must therefore file a registration statement covering their resale within the contractual deadlines stated in the purchase agreement or face standard penalties for late registration. Investors gain immediate economic ownership while the registration process runs in parallel.

This marks the latest capital infusion for the AI-powered medical device developer, which has used similar exempt offerings to fund clinical and regulatory work on its non-invasive diagnostic platforms. The filing also includes Item 9.01 exhibits containing the form of securities purchase agreement, the new CEO’s employment letter, and press-release text describing both the leadership change and the financing.

Primary sources: SEC Form 8-K filed June 3 2026 · Exhibit 10.1 Securities Purchase Agreement · Exhibit 99.1 Press Release.